The protease inhibitor PI*S allele and COPD: a meta-analysis

被引:84
作者
Dahl, M
Hersh, CP
Ly, NP
Berkey, CS
Silverman, E
Nordestgaard, BG
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA
[2] Herlev Univ Hosp, Dept Clin Biochem, Copenhagen, Denmark
[3] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02115 USA
关键词
alpha; 1-antitrypsin; chronic obstructive pulmonary disease; emphysema; heterozygote; meta-analysis;
D O I
10.1183/09031936.05.00135704
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
In many countries, the protease inhibitor (SERPINA1) PI*S allele is more common than PI*Z, the allele responsible for most cases of chronic obstructive pulmonary disease (COPD) due to severe alpha 1-antitrypsin deficiency. However, the risk of COPD due to the PI*S allele is not clear. The current authors located studies that addressed the risk of COPD or measured lung function in individuals with the PI SZ, PI MS and PI SS genotypes. A separate meta-analysis for each genotype was performed. Aggregating data from six studies, the odds ratio (OR) for COPD in PI SZ compound heterozygotes compared with PI MM (normal) individuals was significantly increased at 3.26 (95% confidence intervals (Cl): 1.24-8.57). In 17 cross-sectional and case-control studies, the OR for COPD in PI MS heterozygotes was 1.19 (95%CI: 1.02-1.38). However, PI MS genotype was not associated with COPD risk after correcting for smoking. Furthermore, mean forced expiratory volume in one second, a measure of airflow obstruction and a defining feature of COPD, did not differ between PI MS and PI MM individuals. There were not enough cases to summarise the risk of COPD in PI SS homozygotes. In conclusion, the results show that the PI SZ genotype is a significant risk factor for chronic obstructive pulmonary disease. The risk of chronic obstructive pulmonary disease due to the PI MS genotype is not substantially elevated.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 132 条
[71]  
LAM S, 1979, AM REV RESPIR DIS, V119, P941
[72]   THE FLACCID LUNG SYNDROME AND ALPHA-1-PROTEASE INHIBITOR DEFICIENCY [J].
LAROS, KD ;
BIEMOND, I ;
KLASEN, EC .
CHEST, 1988, 93 (04) :831-835
[73]   GENETIC AND ENVIRONMENTAL DETERMINANTS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE [J].
LARSON, RK ;
BARMAN, ML ;
KUEPPERS, F ;
FUDENBERG, HH .
ANNALS OF INTERNAL MEDICINE, 1970, 72 (05) :627-+
[74]  
LARSSON C, 1976, SCAND J RESPIR DIS, V57, P267
[75]   SMOKING AND INTERMEDIATE ALPHA1-ANTITRYPSIN DEFICIENCY AND LUNG-FUNCTION IN MIDDLE-AGED MEN [J].
LARSSON, C ;
ERIKSSON, S ;
DIRKSEN, H .
BMJ-BRITISH MEDICAL JOURNAL, 1977, 2 (6092) :922-925
[76]  
LEBOWITZ MD, 1978, AM REV RESPIR DIS, V117, P179
[78]   SCREENING FOR HOMOZYGOUS AND HETEROZYGOUS ALPHA1-ANTITRYPSIN DEFICIENCY - PROTEIN ELECTROPHORESIS ON CELLULOSE ACETATE MEMBRANES [J].
LIEBERMAN, J ;
MITTMAN, C ;
SCHNEIDER, AS .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 210 (11) :2055-+
[79]   ALPHA1-ANTITRYPSIN PI-TYPES IN 965-COPD PATIENTS [J].
LIEBERMAN, J ;
WINTER, B ;
SASTRE, A .
CHEST, 1986, 89 (03) :370-373
[80]   A ROLE FOR INTERMEDIATE, HETEROZYGOUS ALPHA-1-ANTITRYPSIN DEFICIENCY IN OBSTRUCTIVE LUNG-DISEASE [J].
LIEBERMAN, J ;
COLP, C .
CHEST, 1990, 98 (03) :522-523